MFC Co Ltd

MFC Co Ltd has a market price of 3600.0 and a market cap of 29073859200.0, with a price-to-earnings ratio of 35.38 and a price-to-book ratio of 0.97. The company's enterprise value to EBITDA is 105.48, and its enterprise value to revenue is 1.4. The return on equity is 0.0273, and the return on assets is 0.023. The company's profitability is reflected in its financials, with a revenue of 20799543230.0, gross profit of 5441476720.0, operating income of 276703540.0, and net income of 821866290.0. The return on equity and return on assets are below the typical thresholds for the Pharmaceuticals industry, indicating that the company's profitability is not significantly above the industry median. MFC Co Ltd operates through two segments: Active Pharmaceutical Ingredient (API) and Key Material, and Improved New Drug API. The company's revenue is primarily concentrated in these segments, with no significant geographic diversification mentioned in the provided data. The company's total assets are 35676109720.0, and its total liabilities are 5620231710.0, with a debt-to-equity ratio of 0.1. The company's growth trajectory is reflected in its operating cash flow of 2387649370.0 and free cash flow of 1217106990.0. The capital expenditure is -642008300.0, indicating a reduction in capital spending. The outlook for the current fiscal year and the next fiscal year is not explicitly provided, but the company's financial performance suggests a stable growth path. The risk assessment for MFC Co Ltd indicates a medium liquidity risk and a low dilution risk. The company has a key flag indicating that net cash is negative after subtracting total debt. The dilution potential is low, and no significant adjustments have been applied to the valuation metrics. Recent events and filings for MFC Co Ltd are not explicitly detailed in the provided data. However, the company's financial snapshot and valuation metrics suggest a stable financial position with moderate liquidity and low dilution risk.